

John Lyons, MSc PhD

VP Translational Research & Development

John Lyons joined Astex as Director of Oncology in October 2003 and in 2007 was named VP of Translational Research with responsibility for the development of strategies for all of Astex's clinical oncology programmes. He has 19 years of industrial experience of cancer biology and clinical development and joined Astex from SuperGen Inc., where, as Senior Director of Scientific Development, he was responsible for the development of Dacogen™ approved for MDS, a form of leukemia. Prior to this, he spent 8 years at Onyx Pharmaceuticals where he led the team that discovered Nexavar, a molecule approved in the US and Europe for renal cell carcinoma and hepatocellular carcinoma. He also worked at Pierre Fabre Medicament in Castres, France and at Cetus Corporation in the US. Dr Lyons is a member of AACR and obtained his PhD in 1989 from the University of Ulm, Germany.